Founded in 2018 in the dynamic city of Hong Kong, Hong Kong Weike Biotechnology Co., Ltd. has quickly established itself as a leader in the biotechnology distribution sector. Specializing in state-of-the-art biotechnological products sourced globally, the company focuses on animal cell culture for scientific research, biopharmaceuticals, and industrial applications. This includes cutting-edge support for areas like recombinant glycoproteins, monoclonal antibodies, and viral particles. With a strong emphasis on cell therapy research, Hong Kong Weike Biotechnology collaborates closely with innovative companies pushing the boundaries of biotechnology today.

As the exclusive distributor in Hong Kong for major Japanese biotechnology companies like ZENOAQ and Matrixome, Inc., Hong Kong Weike Biotechnology takes pride in offering products that meet the highest international standards. All products are certified to EU and US quality requirements in fields such as cytology, microbiology, and immunology. The company ensures strict adherence to all legal regulations, reinforcing its credibility and reputation for delivering safe and reliable solutions. By aligning with internationally acclaimed suppliers, the company provides the local market with world-class resources essential for research breakthroughs and industrial innovations.

Hong Kong Weike Biotechnology serves a diverse network of research institutions, hospitals, and biopharmaceutical manufacturers. Thanks to its comprehensive distribution channels, customers gain immediate access to innovative tools and products required for their vital work. The company’s focus on exceptional service quality and customer satisfaction has solidified its role as a trusted partner in Hong Kong's biotechnology sector. With a commitment to fostering growth and innovation, Hong Kong Weike Biotechnology empowers researchers and manufacturers to achieve new milestones in scientific discovery and healthcare advancements. Together with its partners and clients, the company is driving forward the future of biotechnology in Hong Kong and beyond.